What are the indications for olaparib in breast cancer?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 2, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Indications for Olaparib in Breast Cancer

Olaparib is indicated for two distinct settings in breast cancer: (1) adjuvant treatment of high-risk, early-stage HER2-negative breast cancer with germline BRCA1/2 mutations after completion of chemotherapy and local treatment, and (2) metastatic HER2-negative breast cancer with germline BRCA1/2 mutations.

Adjuvant Setting (Early-Stage Disease)

For patients with early-stage, HER2-negative breast cancer who have germline BRCA1 or BRCA2 pathogenic/likely pathogenic variants and high risk of recurrence, one year of adjuvant olaparib should be offered after completion of (neo)adjuvant chemotherapy and local treatment, including radiation 1.

Specific Eligibility Criteria for Adjuvant Olaparib:

For patients who had surgery first:

  • Triple-negative breast cancer (TNBC): Tumor size >2 cm OR any involved axillary lymph nodes
  • Hormone receptor-positive (HR+) disease: At least 4 involved axillary lymph nodes 1

For patients who had neoadjuvant chemotherapy:

  • TNBC: Any residual cancer after neoadjuvant therapy
  • HR+ disease: Residual disease AND CPS-EG score ≥3 (clinical stage, pathologic stage, estrogen receptor, and tumor grade score) 1

Key Evidence Points:

The OlympiA trial demonstrated significantly longer invasive disease-free survival and distant disease-free survival with one year of adjuvant olaparib compared to placebo (median follow-up 2.5 years). The treatment showed manageable safety and tolerability with no significant problems in quality of life 1. This represents a strong ASCO recommendation based on high-quality evidence 1.

Metastatic Setting

Patients with metastatic HER2-negative breast cancer who are candidates for PARP inhibitor treatment should undergo testing for germline BRCA1 and BRCA2 pathogenic or likely pathogenic mutations to determine eligibility for olaparib or talazoparib 2.

Evidence for Metastatic Disease:

The OlympiAD trial demonstrated that olaparib monotherapy provided:

  • Median progression-free survival: 7.0 months vs 4.2 months with standard chemotherapy (HR 0.58; 95% CI 0.43-0.80)
  • Response rate: 59.9% vs 28.8% with chemotherapy
  • 42% lower risk of disease progression or death
  • Better quality of life compared to chemotherapy (except for nausea/vomiting scores)
  • Lower grade 3+ adverse events: 36.6% vs 50.5% with chemotherapy 2

Extended follow-up data showed particularly strong benefit in first-line metastatic disease, with median OS of 22.6 months for olaparib versus 14.7 months for chemotherapy (HR 0.55), and 3-year survival of 40.8% versus 12.8% 3.

Critical Implementation Points

Testing Requirements:

All patients with HER2-negative breast cancer being considered for PARP inhibitor therapy must undergo germline BRCA1/2 testing before treatment initiation 2. This is a prerequisite for both adjuvant and metastatic indications.

Treatment Duration:

  • Adjuvant setting: Exactly 1 year of treatment 1
  • Metastatic setting: Continue until disease progression or unacceptable toxicity 2

Common Pitfalls to Avoid:

  1. Do not use olaparib in patients without confirmed germline BRCA1/2 pathogenic variants - the evidence specifically supports use only in this population 2, 1

  2. In the adjuvant setting, ensure patients meet high-risk criteria - not all BRCA mutation carriers with early breast cancer qualify. The specific tumor size, nodal involvement, and residual disease criteria must be met 1

  3. Adjuvant olaparib requires prior completion of chemotherapy - 95% of patients in OlympiA received chemotherapy, and the indication is specifically for post-chemotherapy use 1

  4. Monitor for hematologic malignancies - PARP inhibitors are DNA-interacting drugs with potential to induce myelodysplastic syndrome and acute myelogenous leukemia, requiring ongoing surveillance 1

Sequencing Considerations:

In the metastatic setting, olaparib shows greatest benefit when used in first-line rather than after multiple prior chemotherapy lines, with substantially improved overall survival in this population 3. For metastatic patients, olaparib is approved after no more than 2 prior chemotherapy regimens 2.

References

Related Questions

According to the OLYMPIA trial, what is the recommended adjuvant olaparib regimen (dose, duration, monitoring, and alternatives if contraindicated) for early‑stage high‑risk HER2‑negative breast cancer patients with a germline BRCA1 or BRCA2 pathogenic variant who have completed surgery, radiation, and anthracycline‑taxane‑based chemotherapy (and endocrine therapy if hormone‑receptor‑positive)?
What are the inclusion and exclusion criteria for the OlympiA trial (olaparib) in adults (≥18 years) with HER2‑negative early‑stage (stage II‑III) breast cancer and a germline BRCA1/BRCA2 pathogenic variant?
What are the study arms in the low-dose tamoxifen (Lo Tam) trial for post‑menopausal women with hormone‑positive, HER2‑negative early‑stage, low‑molecular‑risk breast cancer?
What is the appropriate indication, dosing regimen, and monitoring for Olaparib in patients with triple‑negative breast cancer who have a germline BRCA1 or BRCA2 mutation and have received prior chemotherapy?
In patients with BRCA‑mutated metastatic breast cancer with bone metastases, how does the hematologic toxicity of olaparib (generic) compare to that of talazoparib (generic)?
What is the most likely diagnosis and recommended workup and treatment for a patient presenting with hyperreflexia, hypertonia, cogwheel rigidity, and fasciculations?
What premixed insulin formulations and initial dosing schedule are recommended for an adult with type 2 diabetes requiring insulin therapy?
Which antibiotic should be combined with vancomycin to achieve optimal synergistic bactericidal activity?
In a 37‑week gestational age infant with a positive direct Coombs test, is there a specific reticulocyte count or hemoglobin level cutoff that determines when to administer intravenous immunoglobulin (IVIG) or perform exchange transfusion for hyperbilirubinemia?
How should the Mini‑Mental State Examination (MMSE) be used to screen for cognitive impairment after traumatic brain injury (TBI)?
Can telmisartan cause angioedema?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.